

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Sihuan Pharmaceutical Holdings Group Ltd.

四環醫藥控股集團有限公司

(incorporated in Bermuda with limited liability)

(Stock Code: 0460)

**VOLUNTARY ANNOUNCEMENT
MARKETING APPROVAL FOR THE THIRD INDICATION OF
XUANYUENING (BIREOCICLIB TABLETS)
FOR THE FIRST-LINE TREATMENT OF HR+/HER2-
ADVANCED BREAST CANCER GRANTED BY THE NMPA**

The board of directors (the “**Board**”) of Sihuan Pharmaceutical Holdings Group Ltd. (the “**Company**” or “**Sihuan Pharmaceutical**”, together with its subsidiaries, the “**Group**”) is pleased to announce that the marketing approval for the new indication regarding the supplemental New Drug Application (“**sNDA**”) of the innovative drug Bireociclib Tablets (brand name: Xuanyuening), independently developed by the Group’s non wholly-owned subsidiary Xuanzhu Biopharmaceutical Co., Ltd. (“**Xuanzhu Biopharm**”), in combination with aromatase inhibitor (“**AI**”) for the treatment of first-line treatment of hormone receptorpositive (HR+) and human epidermal growth factor receptor 2-negative (HER2-) (“**HR+/HER2-**”) advanced breast cancer has been granted by the National Medical Products Administration of China (“**NMPA**”). This marks the third indication approved in China following the approvals for combined use with fulvestrant and as an indication of single drug treatment. Consequently, Bireociclib has become the first and only drug in China covering the entire spectrum of first-line, second-line, and later-line treatments of HR+/HER2- advanced breast cancer. This expansion of the approved indication to include first-line treatment of HR+/HER2- advanced breast cancer significantly broadens patient coverage, effectively enhances the clinical value and drug accessibility of the product, and provides robust support for its future sales growth.

Breast cancer is the most diagnosed malignant tumor among women worldwide. Reports from China Insights Consultancy indicated that the number of new breast cancer cases in China increased from 322,200 in 2018 to 374,700 in 2024 and is expected to reach 435,000 by 2032. HR+/HER2- breast cancer is the most prevalent subtype in China, accounting for approximately 75% of total cases. Among HR+/HER2- breast cancer patients, about 30% were diagnosed with advanced breast cancer. In China, CDK4/6 inhibitors combined with endocrine therapy for HR+/HER2- advanced breast cancer have become the standard first-line treatment, and the market size for CDK4/6 inhibitors in China is expected to reach RMB13 billion by 2032.

The approval of this new indication is mainly based on the data results from the BRIGHT-3 study (NCT05257395). The BRIGHT-3 study is a randomized, double-blind Phase III clinical trial conducted across 58 centers in China, aiming to evaluate the efficacy and safety of Bireociclib in combination with letrozole or anastrozole for the first-line treatment of HR+/HER2- advanced breast cancer. Prior to that, the research results of BRIGHT-3 were first published in the European Society for Medical Oncology (“**ESMO 2025**”). Results of this interim analysis showed that, in terms of efficacy, the median Progression-Free Survival (mPFS) for the Bireociclib group assessed by both the investigators and the independent review committee had not been reached, compared to 18.43 months and 19.55 months for the control group, respectively. The fact that mPFS has not been reached suggests that more patients in the Bireociclib group have not yet experienced disease progression, reflecting its durable efficacy advantage. Compared with endocrine therapy combined with placebo, the Bireociclib regimen can reduce the risk of disease progression or death by 47%. Notably, in patients with liver metastases (specifically with a poor prognosis), the disease progression or death risk was significantly reduced by 64%, demonstrating its outstanding potential in the refractory population. In the intention-to-treat population, the objective response rate (ORR) in the Bireociclib group reached 63.5%, significantly superior to 42.5% in the control group. In terms of safety, common adverse events of the Bireociclib combination regimen (such as diarrhea and neutropenia) were mostly Grade 1–2, which can be effectively managed through supportive care or dose adjustment, with overall controllable safety.

ABOUT BIREOCICLIB

Bireociclib Tablets (brand name: Xuanyuening), as the first approved CDK2/4/6 inhibitor in China, possesses a unique multi-target synergistic mechanism of action, offering advantages such as potent inhibition of tumor cell proliferation and a significant reduction in hematological toxicity commonly associated with traditional CDK4/6 inhibitors. Bireociclib was approved by the National Medical Products Administration in May 2025, for use in combination with Fulvestrant for the treatment of patients with HR+/HER2- advanced or metastatic breast cancer whose disease has progressed after prior endocrine therapy, and as a monotherapy for HR+/HER2- advanced or metastatic breast cancer patients who have progressed after receiving two or more lines of endocrine therapies and one chemotherapy in

the metastatic stage, making it the first and only CDK2/4/6 inhibitor in China approved for a monotherapy indication. PharmCube statistics indicated that Bireociclib also ranked first in the global CDK2/4/6 inhibitor market. In December 2025, the two approved indications of Bireociclib Tablets have been included in the National Reimbursement Drug List for Basic Medical Insurance, Maternity Insurance and Work-Related Injury Insurance (2025), effective on January 1, 2026.

ABOUT XUANZHU BIOPHARM

Xuanzhu Biopharm is the innovative drug subsidiary of Sihuan Pharmaceutical. It is an innovative pharmaceutical company with roots in China and a global perspective, focusing on major diseases such as digestion, oncology and non-alcoholic steatohepatitis, and is committed to the research and development, production and commercialization of class 1 drugs with core proprietary intellectual property rights. The company has a first-class R&D team, all core personnel have years of experience in new drug research and development. The company has two R&D platforms: small molecule chemistry and large molecule biologics. The dual engines drive the company's innovation and development, forming a product pipeline that covers small molecule chemistry, large molecule biopharmaceuticals, antibody-drug conjugate (ADC) and other types of products. With a focus on unmet major clinical needs, the company is committed to developing into a first-class innovative pharmaceutical company with independent research and development, production, and sales capabilities.

ABOUT SIHUAN PHARMACEUTICAL

Founded in 2001 and listed on the Main Board of The Stock Exchange of Hong Kong Limited in 2010, Sihuan Pharmaceutical is an international medical aesthetic and pharmaceutical company led by innovation, with an independent and leading research and development technology platform, a rich global product pipeline, strong product registration capability, a full dosage form production platform with high efficiency and low cost and a mature and excellent sales system. Adhering to the overall strategic goal for the “full promotion of a two-wheel drive strategy of its medical aesthetics and biopharmaceutical businesses”, Sihuan Pharmaceutical endeavors to build itself into a leading medical aesthetics and biopharmaceutical company in China.

This announcement is being made by the Company on a voluntary basis to update the investing public on the Group's latest business development, and does not constitute, and is not intended to be, an advertisement regarding the use of any medicine, surgical appliance, treatment or orally consumed product.

By order of the Board
Sihuan Pharmaceutical Holdings Group Ltd.
Dr. Che Fengsheng
Chairman and Executive Director

Hong Kong, 3 March 2026

As at the date of this announcement, the executive directors of the Company are Dr. Che Fengsheng (Chairman), Dr. Guo Weicheng (Deputy Chairman and Chief Executive Officer), Dr. Zhang Jionglong, Ms. Chen Yanling and Ms. Miao Guili; and the independent non-executive directors of the Company are Mr. Tsang Wah Kwong, Dr. Zhu Xun and Mr. Wang Guan.